undamentalytics Newsletter
Sign in

Scynexis Inc (SCYX) stock

Add to watchlist

Add holding +

NASDAQ: SCYX Nasdaq Biotechnology Next results ~November 4, 2026

B Fundamentals grade

Scynexis Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$2.3

Price-to-sales vs peers

Base case. Range ~$2.3–$18. Sales per share times peers' typical price-to-sales; used only when earnings are negative.

Price vs value

No Buy/Hold/Sell rating is issued: only 1 valuation models apply; a rating needs 3.

Scynexis Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 0 selling1 purchase and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds39 adding, 0 cuttingOf 7 active managers that changed their stake, 7 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Scynexis files

Where Scynexis stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $19m, up 489.8% on a year earlier, slower than the 673.5% growth a quarter earlier. That growth ranks 12 of 122 among the biotechnology companies we cover. Free-cash-flow margin rose to -69.3% from -739.8% a year earlier. Operating margin widened to -117.6% from -1121.7%. Against its peers on growth, profitability, cash generation and balance sheet, it grades B. It passes 2 of our 2 financial-health checks. Our price-to-sales vs peers value is $4.16 a share.

Source: 10-Q filed August 10, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Scynexis Inc's trailing-twelve-month revenue grew 489.8% year on year, with a free-cash-flow margin of -69.3%. Where it stands out: revenue growth of 489.8% ranks 16 of 172 biotechnology companies we cover. Where it lags: change in growth rate of -183.8pp ranks 164 of 172 biotechnology companies we cover.

Current signal Revenue growth decelerating: TTM revenue growth slowed to 489.8% (-183.8pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 489.8% over the last 12 months, against a median of 12.6% for biotechnology companies we cover.
  • Margins widening. Operating margin is up 1004.1 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Growth slowing. The growth rate is 183.8 points lower than a quarter earlier.
  • Loss-making. Operating margin is -117.6%: costs exceed revenue.
  • Burning cash. Free cash flow was -69.3% of revenue over the last 12 months.
  • Volatile shares. Over the past year the shares showed annualised volatility of 73% and a beta of 1.4 against the S&P 500.

Latest results: FY2026 Q2

Filed August 10, 2026
Earnings per share
$0.63 against an average estimate of -$0.51: beat by 224.3%
Revenue
$0m, down 82.8% on a year earlier
Next report
November 4, 2026; average EPS estimate -$0.72

Scynexis' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+1.1%
  • 1 week0.0%
  • 1 month-25.6%
  • This year-24.6%
  • 1 year-27.8%
  • 5 years-91.3%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$19.2M
Operating margin
-117.6%
Net margin
-53.3%
EPS (TTM, diluted)
$-1.66

Growth

Revenue growth
+489.8%
Change in growth rate
−183.8 pts
Share count change
+1.9%

Cash

Free cash flow (TTM)
-$13.3M
FCF margin
-69.3%
Stock pay % of revenue
12.3%

Earnings

Last results
March 28, 2024

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Leadership
  3. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Scynexis Inc valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 1 valuation models apply; a rating needs 3.

Valuation models

We value Scynexis Inc as an operating company, with every model that fits that kind of business. Cost of equity 10.4%: the 10-year Treasury yield (4.9%) plus a beta of 1.21 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$2.3 ~$5.5–$18 Included, half weight
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$2.3 ~$2.3–$18 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Scynexis Inc with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025
Share price$496.80$255.20$185.60$38.56$72.80$61.20$48.80$12.48$17.84$9.68$5.06
Market value$1.2bn$972m$993m$338m$817m$656m$1.3bn$532m$863m$470m$252m
+ Net debt (− = net cash)−$47m−$21m$3m$4m−$42m−$93m−$69m−$11m−$34m−$16m−$21m
Enterprise value$1.2bn$950m$996m$342m$775m$563m$1.2bn$521m$829m$454m$231m
Multiples
Price / sales n/mn/mn/mn/mn/m—97.8x104.5x6.2x125.4x12.3x
Price / earnings ————————12.9x——
Price / free cash flow ————————14.4x——
EV / EBITDA ————————11.3x——

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

9 /100

Weak moat

How hard Scynexis's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -36.4% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -1893.1%; its worst year was -23569.2%.

  • Cash conversion 1 / 20

    Free cash flow was positive in 1 of 10 years, at a median -1597.5% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 806.7% over five years; stock-based pay has been a median 104.8% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (14 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, after the close. Analysts expect revenue of $87000 and EPS of −$0.72 (range −$0.79 to −$0.65) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$2.91 −114% $619500 −97%
Next −$2.31 +20% $7m +978%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −28.7% on 90 days ago. In the last 30 days, 1 analyst raised Scynexis Inc's forecast and 0 cut it.

Consensus EPS forecast Scynexis Inc, last 90 days
−$6.00 −$4.00 −$2.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$4.08 Current fiscal year, 60 days ago: −$4.08 Current fiscal year, 30 days ago: −$4.08 Current fiscal year, 7 days ago: −$4.08 Current fiscal year, Now: −$2.91 −$2.91 Next fiscal year, 90 days ago: −$1.95 Next fiscal year, 60 days ago: −$2.52 Next fiscal year, 30 days ago: −$2.52 Next fiscal year, 7 days ago: −$2.52 Next fiscal year, Now: −$2.31 −$2.31

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$4.08−$1.95
60 days ago −$4.08−$2.52
30 days ago −$4.08−$2.52
7 days ago −$4.08−$2.52
Now −$2.91−$2.31

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.51 $0.63 +224.3%
Mar 2026 −$0.99 −$3.36 −240.5%
Dec 2025 $1.01 $2.00 +97.4%
Sept 2025 −$1.60 −$1.36 +15.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

3 analysts, Oct 2026
Buy3100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026123
  2. Sep 2026123
  3. Aug 2026123
  4. Jul 2026123

Counts of recommendations published by analysts covering Scynexis Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
4.3%
of tradable shares
Days to cover
0.85
at average volume
Short interest, 1 month
−9%
to October 15, 2026
Held by institutions
62%
of shares
Held by insiders
2.1%
of shares
Employees
18
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −27.8%

$5.28 on October 31, 2025 to $3.81

ThenNowEffect
Revenue (last 12 months) $3m $19m +489.8%
P/S multiple 9.9x 1.5x −84.7%
Share count 6m 8m −20.0%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −74.7%

$15.04 on November 3, 2023 to $3.81

ThenNowEffect
Revenue (last 12 months) $136m $19m −85.8%
P/S multiple 0.7x 1.5x +128.8%
Share count 6m 8m −21.8%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
SCYX−20%−74%+43%−46%−48%−25%
Industry peers (median)−36%−56%−18%−28%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
SCYX33%25%50%42%33%64%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
SCYX−51%−78%−58%−64%−60%−60%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 3, 2015: 99% from November 10, 2015 to July 27, 2026. Getting back needed a 15698% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$3.57 – $8.88
From 52-week high
−57.1%
vs 50-day average
−16.0%
vs 200-day average
−31.2%
Volatility (1 year)
73%
Beta vs S&P 500
1.45

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 4 down
typical move ±8.9%
After a week
3 up, 5 down
typical move ±13.2%
After a month
3 up, 5 down
typical move ±20.9%
Results releasedNext dayS&P 500 next day5 days21 days
March 28, 2024 +4.6% −0.2% +20.0% +27.7%
November 9, 2022 −14.7% +3.3% −9.8% −5.4%
August 15, 2022 +0.7% +0.6% −9.8% +2.1%
May 12, 2022 +10.7% +2.3% +12.3% −5.3%
March 29, 2022 −14.5% +0.6% −18.5% −45.1%
November 10, 2021 −5.9% −0.8% +19.3% +27.7%
March 5, 2018 −13.0% +1.4% −11.5% −18.2%
October 5, 2016 +7.3% +0.5% −4.2% −36.1%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Scynexis Inc in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Scynexis Inc
$0 $50M $100M $150M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $135.9M Revenue (TTM), FY23 Q4: $140.1M Revenue (TTM), FY24 Q1: $140.4M Revenue (TTM), FY24 Q2: $9.7M Revenue (TTM), FY24 Q3: $8.6M Revenue (TTM), FY24 Q4: $3.7M Revenue (TTM), FY25 Q1: $2.6M Revenue (TTM), FY25 Q2: $3.3M Revenue (TTM), FY25 Q3: $2.9M Revenue (TTM), FY25 Q4: $20.6M Revenue (TTM), FY26 Q1: $20.3M Revenue (TTM), FY26 Q2: $19.2M $19.2M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $135.9M
FY23 Q4 $140.1M
FY24 Q1 $140.4M
FY24 Q2 $9.7M
FY24 Q3 $8.6M
FY24 Q4 $3.7M
FY25 Q1 $2.6M
FY25 Q2 $3.3M
FY25 Q3 $2.9M
FY25 Q4 $20.6M
FY26 Q1 $20.3M
FY26 Q2 $19.2M
Revenue growth, TTM YoY Scynexis Inc
-1000% 0% 1000% 2000% 3000% 4000% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 3162.9% Revenue growth, TTM YoY, FY23 Q4: 2652.7% Revenue growth, TTM YoY, FY24 Q1: 2436.8% Revenue growth, TTM YoY, FY24 Q2: -92.9% Revenue growth, TTM YoY, FY24 Q3: -93.7% Revenue growth, TTM YoY, FY24 Q4: -97.3% Revenue growth, TTM YoY, FY25 Q1: -98.1% Revenue growth, TTM YoY, FY25 Q2: -66.3% Revenue growth, TTM YoY, FY25 Q3: -65.8% Revenue growth, TTM YoY, FY25 Q4: 449.9% Revenue growth, TTM YoY, FY26 Q1: 673.5% Revenue growth, TTM YoY, FY26 Q2: 489.8% 489.8%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 3162.9%
FY23 Q4 2652.7%
FY24 Q1 2436.8%
FY24 Q2 -92.9%
FY24 Q3 -93.7%
FY24 Q4 -97.3%
FY25 Q1 -98.1%
FY25 Q2 -66.3%
FY25 Q3 -65.8%
FY25 Q4 449.9%
FY26 Q1 673.5%
FY26 Q2 489.8%
Operating margin (TTM) Scynexis Inc
-1500% -1000% -500% 0% 500% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: 53.9% Operating margin (TTM), FY23 Q4: 51.9% Operating margin (TTM), FY24 Q1: 52.6% Operating margin (TTM), FY24 Q2: -537.0% Operating margin (TTM), FY24 Q3: -608.6% Operating margin (TTM), FY24 Q4: -990.9% Operating margin (TTM), FY25 Q1: -1377.2% Operating margin (TTM), FY25 Q2: -1121.7% Operating margin (TTM), FY25 Q3: -1181.1% Operating margin (TTM), FY25 Q4: -77.9% Operating margin (TTM), FY26 Q1: -119.9% Operating margin (TTM), FY26 Q2: -117.6% -117.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 53.9%
FY23 Q4 51.9%
FY24 Q1 52.6%
FY24 Q2 -537.0%
FY24 Q3 -608.6%
FY24 Q4 -990.9%
FY25 Q1 -1377.2%
FY25 Q2 -1121.7%
FY25 Q3 -1181.1%
FY25 Q4 -77.9%
FY26 Q1 -119.9%
FY26 Q2 -117.6%
FCF margin (TTM) Scynexis Inc
-1500% -1000% -500% 0% 500% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: 33.2% FCF margin (TTM), FY23 Q4: 42.9% FCF margin (TTM), FY24 Q1: 53.5% FCF margin (TTM), FY24 Q2: -105.3% FCF margin (TTM), FY24 Q3: -254.9% FCF margin (TTM), FY24 Q4: -640.9% FCF margin (TTM), FY25 Q1: -1044.4% FCF margin (TTM), FY25 Q2: -739.8% FCF margin (TTM), FY25 Q3: -1145.7% FCF margin (TTM), FY25 Q4: -25.6% FCF margin (TTM), FY26 Q1: -29.1% FCF margin (TTM), FY26 Q2: -69.3% -69.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 33.2%
FY23 Q4 42.9%
FY24 Q1 53.5%
FY24 Q2 -105.3%
FY24 Q3 -254.9%
FY24 Q4 -640.9%
FY25 Q1 -1044.4%
FY25 Q2 -739.8%
FY25 Q3 -1145.7%
FY25 Q4 -25.6%
FY26 Q1 -29.1%
FY26 Q2 -69.3%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 17 12 0 0 0 0 0 0 13 5 140 4 21 19
Gross profit 1 4 — — — — — — — — — — — —
EBITDA −6 −13 −28 −28 −26 −30 −49 −51 −60 −85 73 −37 — —
Operating income −7 −15 −28 −28 −26 −30 −49 −51 −61 −86 73 −37 −16 −23
Net income −47 −6 −33 −30 −25 −12 −54 −55 −33 −63 67 −21 −9 −10
Diluted EPS −$34.87 −$6.72 −$1.34 −$7.90 — — — — −$1.25 −$1.47 $1.39 −$0.44 −$0.17 —
Growth (year on year)
Revenue — −30.4% −97.8% 0.0% 0.0% 0.0% −52.9% −100.0% — −61.3% +>999% −97.3% +449.9% +489.8%
EBITDA — — — — — — — — — — — −150.7% — —
Operating income — — — — — — — — — — — −151.1% — —
Net income — — — — — — — — — — — −131.8% — —
Diluted EPS — — — — — — — — — — — −131.7% — —
Margins
Gross margin 3.3% 30.5% — — — — — — — — — — — —
EBITDA margin −34.9% −114.3% <−999% <−999% <−999% <−999% <−999% — −459.3% <−999% 52.3% −990.8% — —
Operating margin −42.7% −124.8% <−999% <−999% <−999% <−999% <−999% — −462.2% <−999% 51.9% −990.8% −78.0% −117.6%
Net margin −277.7% −50.0% <−999% <−999% <−999% <−999% <−999% — −249.7% <−999% 47.8% −568.3% −41.8% −53.3%
Free-cash-flow margin −28.1% −86.7% <−999% <−999% <−999% <−999% <−999% — −414.5% <−999% 42.9% −640.9% −25.6% −69.3%
Cash flow
Cash from operations −4 −9 −25 −29 −25 −28 −38 −49 −55 −80 60 −24 −5 −13
Capital spending 0 1 1 0 0 1 0 0 0 0 0 0 0 0
Free cash flow −5 −10 −25 −29 −25 −29 −38 −49 −55 −80 60 −24 −5 −13
Stock-based pay 0 1 3 1 2 2 2 2 2 4 3 3 3 2
Free cash flow after stock pay −5 −11 −28 −31 −26 −31 −40 −52 −57 −84 58 −27 −8 −16
Balance sheet
Cash 1 32 47 36 11 11 42 93 104 46 34 16 21 10
Total debt 15 0 0 14 15 15 0 0 35 35 — 0 0 0
Net debt (negative = net cash) 14 −32 −47 −21 3 4 −42 −93 −69 −11 −34 −16 −21 −10
Diluted shares — 2m 2m 4m 5m 9m 11m 11m 26m 43m 48m 49m 50m —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $75m
Short-term assets $56mLonger-term assets $19m
What it owes, and who funded it · $75m
Short-term liabilities $6mLonger-term liabilities $2mShareholders' equity $67m
  • Short-term assets cover short-term liabilities $56m of assets due within a year against $6m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $56m short-term assets against $2m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Scynexis Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+1.9%
year over year
R&D spending
136.6%
of revenue
Sales & admin spending
81.1%
of revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated SCYX CELU CTMX PRQR JANX KROS Median
Revenue, last 12 months $19m $19m $18m $18m $24m $15m $56m
Revenue growth, last 12 months 489.8% −58.1% −87.0% −12.1% >999% −93.6% 12.6%
Revenue growth, 3-year average −47.9% 7.2% −38.7% — 45.7% — 13.7%
Revenue growth, latest quarter −82.8% −5.3% −92.4% — >999% −100.0% 10.2%
Gross margin 26.0% 19.2% — — — — 82.9%
Operating margin −117.6% −264.3% −476.2% −273.1% −598.1% −682.3% −189.4%
Operating margin, 3-year average −592.1% −204.2% −146.9% — <−999% <−999% −363.5%
Net margin −53.3% −245.7% −435.2% −265.2% −427.5% −559.2% −169.8%
Cash from operations / revenue −69.3% −47.8% −450.3% −331.9% −171.9% −322.7% −168.0%
Free-cash-flow margin −69.3% −80.1% −450.7% −338.3% −174.7% −326.1% −162.4%
Free-cash-flow margin, 3-year average −304.8% −50.3% −192.6% — <−999% <−999% −310.0%
Stock pay / revenue 12.3% 66.5% 55.4% 25.2% 153.7% 153.8% 20.0%
Change in share count 1.9% 24.7% 88.7% 22.4% 6.2% −31.6% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 489.8% 12.6% 16 of 172
Change in growth rate Growth -183.8pp -0.1pp 164 of 172
Operating margin Profitability -117.6% -189.4% 77 of 175
Net margin Profitability -53.3% -157.3% 65 of 180
Free-cash-flow margin Cash generation -69.3% -145.4% 74 of 176
Stock pay as % of revenue Cash generation 12.3% 19.2% 71 of 179
Change in share count Balance sheet 1.9% 7.9% 45 of 156

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Licenses and services $19.2M 93.0% ▲ 411.4%
Products $1.4M 7.0% —

From Scynexis Inc's 10-K filed March 4, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$20.9M
Institutions reporting
39
Positions opened / closed
39 / 0

Top buyers and sellers, Q2 2026: 39 institutions bought and 0 sold ; the biggest buyer was Great Point Partners LLC (+944K shares) . See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Great Point Partners LLC $3.8M 944K 18.3% —
Squadron Capital Management LLC $3.1M 757K 14.7% —
Adage Capital Partners Gp, L.L.C. $2.2M 543K 10.6% —
Propel Bio Management, LLC $2.2M 543K 10.6% —
Woodline Partners LP $1.6M 388K 7.5% —
Vanguard Capital Management LLC $1.2M 297K 5.8% —
Avidity Partners Management LP $1.1M 260K 5.1% —
Kingdon Capital Management, L.L.C. $1M 248K 4.8% —
Millennium Management LLC $735,807 181K 3.5% —
Heights Capital Management, Inc $612,743 151K 2.9% —
Dafna Capital Management LLC $552,983 136K 2.6% —
Empery Asset Management, LP $514,656 126K 2.5% —

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Scynexis Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 1 trade by 1 insider, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying
Insider Date Trade Shares Price Value
Angulo Gonzalez David Chief Executive Officer April 1, 2026 Buy 108,695 — $0

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • March 28, 2024
  • November 9, 2022
  • August 15, 2022
  • May 12, 2022
  • March 29, 2022
  • November 10, 2021

Recent SEC filings

Data status

When each part of this page on Scynexis Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Scynexis Inc in brief

What does Scynexis Inc do?
Scynexis Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Scynexis Inc's stock ticker?
Scynexis Inc trades under the ticker SCYX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Scynexis Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Scynexis Inc reported revenue of $19.2M, 489.8% higher than a year earlier, according to its SEC filings.
What is Scynexis Inc's free cash flow?
Scynexis Inc's free-cash-flow margin is -69.3% of revenue over the trailing twelve months, ranking 74 of the 176 biotechnology companies we cover.
Who are Scynexis Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Great Point Partners LLC, Squadron Capital Management LLC and Adage Capital Partners Gp, L.L.C. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Scynexis Inc's market cap?
On December 31, 2025, Scynexis Inc's market capitalisation was about $252M and net debt of -$21.3M. Market figures come from third-party market data and may be delayed.
Who are Scynexis Inc's competitors?
In our Biotechnology peer group, the companies closest to Scynexis Inc are Celularity Inc, Cytomx Therapeutics, Inc., Proqr Therapeutics N.V., Janux Therapeutics, Inc. and Keros Therapeutics, Inc. The side-by-side comparison below sets their revenue, margins and growth against Scynexis Inc's.
Are insiders buying or selling Scynexis Inc stock?
Over the last 12 months, Scynexis Inc's directors and officers reported 1 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Scynexis Inc's next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Scynexis Inc announces its own schedule.